Arnold Suzanne V
SAINT LUKE'S MID AMERICA HEART INSTITUTE, UNIVERSITY OF MISSOURI-KANSAS CITY, KANSAS CITY, MISSOURI.
Methodist Debakey Cardiovasc J. 2018 Jan-Mar;14(1):7-13. doi: 10.14797/mdcj-14-1-7.
The major goals of treating ischemic heart disease are to reduce angina, improve quality of life, and ultimately reduce mortality. While medical therapy can effectively address these aims, there is still much research and debate about the role of percutaneous coronary intervention in the treatment spectrum-specifically, whether or not stenting prolongs life or simply treats symptoms without impacting survival. The data supporting revascularization for survival benefit came from patients who underwent bypass graft surgery prior to the introduction of effective medical management. Although both physicians and patients continue to believe in the life-saving ability of coronary stenting, little data exist to support this belief outside of when used during an acute myocardial infarction. Strategy trials designed to test the benefit of coronary stenting have limitations that have curbed physicians' willingness to accept the results, but they provide the best evidence for how to optimally manage these patients. In this article, we explore the data supporting the use of coronary stenting for various indications and the questions that remain to be answered.
治疗缺血性心脏病的主要目标是减轻心绞痛、改善生活质量并最终降低死亡率。虽然药物治疗能够有效实现这些目标,但关于经皮冠状动脉介入治疗在整个治疗体系中的作用,仍存在大量研究和争议——具体而言,支架置入术究竟是能延长生命,还是仅仅缓解症状而不影响生存率。支持血管重建以获得生存获益的数据来自于在有效药物治疗出现之前接受搭桥手术的患者。尽管医生和患者仍然相信冠状动脉支架置入术具有挽救生命的能力,但除了在急性心肌梗死期间使用外,几乎没有数据支持这一观点。旨在测试冠状动脉支架置入术益处的策略试验存在局限性,这抑制了医生接受试验结果的意愿,但它们为如何最佳管理这些患者提供了最好的证据。在本文中,我们探讨了支持冠状动脉支架置入术用于各种适应症的数据以及仍有待解答的问题。